Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Schisandra chinensis (called bei-wuweizi in Chinese, S. chinensis) and Schisandra sphenanthera (called nan-wuweizi in Chinese, S. sphenanthera) are two highly similar plants in the Magnoliaceae family. Their dried ripe fruits are commonly used as traditional Chinese medicine in the treatment of coughs, palpitation, spermatorrhea, and insomnia. They also are traditionally used as tonics in Russia, Japan, and Korea.AIM OF THE REVIEW: S. chinensis and S. sphenanthera are similar in appearance, traditional applications, ingredient compositions, and therapeutic effects. This review, therefore, aims to provide a systematic insight into the botanical background, ethnopharmacology, phytochemistry, pharmacology, pharmacokinetics, quality control, and toxicology of S. chinensis and S. sphenanthera, and to explore and present the similarities and differences between S. chinensis and S. sphenanthera.MATERIALS AND METHODS: A comprehensive literature search regarding S. chinensis and S. sphenanthera was collected by using electronic databases including PubMed, SciFinder, Science Direct, Web of Science, CNKI, and the online ethnobotanical database.RESULTS: In the 2020 Edition of Chinese Pharmacopoeia (ChP), there were 100 prescriptions containing S. chinensis, while only 11 contained S. sphenanthera. Totally, 306 and 238 compounds have been isolated and identified from S. chinensis and S. sphenanthera, respectively. Among these compounds, lignans, triterpenoids, essential oils, phenolic acid, flavonoids, phytosterols are the major composition. Through investigation of pharmacological activities, S. chinensis and S. sphenanthera have similar therapeutic effects including hepatoprotection, neuroprotection, cardioprotection, anticancer, antioxidation, anti-inflammation, and hypoglycemic effect. Besides, S. chinensis turns out to have more effects including reproductive regulation and immunomodulatory, antimicrobial, antitussive and antiasthmatic, anti-fatigue, antiarthritic, and bone remodeling effects. Both S. chinensis and S. sphenanthera have inhibitory effects on CYP3A and P-gp, which can mediate metabolism or efflux of substrates, and therefore interact with many drugs.CONCLUSIONS: S. chinensis and S. sphenanthera have great similarities. Dibenzocyclooctadiene lignans are regarded to contribute to most of the bioactivities. Schisandrin A-C, schisandrol A-B, and schisantherin A, existing in both S. chinensis and S. sphenanthera but differing in the amount, are the main active components, which may contribute to the similarities and differences. Study corresponding to the traditional use is needed to reveal the deep connotation of the use of S. chinensis and S. sphenanthera as traditional Chinese medicine. In addition, a joint study of S. chinensis and S. sphenanthera can better show the difference between them, which can provide a reference for clinical application. It is worth mentioning that the inhibition of S. chinensis and S. sphenanthera on CYP3A and P-gp may lead to undesirable drug-drug interactions.

Research Progress on the Pharmacological Action of Schisantherin A

[Study on Main Pharmacodynamic Effects for Schisandra Lignans Based Upon Network Pharmacology].

A review: Pharmacology and pharmacokinetics of Schisandrin A

Schisandrin B Ameliorated Chondrocytes Inflammation and Osteoarthritis Via Suppression of NF-κB and MAPK Signal Pathways.

Discovery of Novel Anti-Parkinsonian Effect of Schisantherin A in in Vitro and in Vivo.

Schizandrin A Protects Against Cerebral Ischemia-Reperfusion Injury by Suppressing Inflammation and Oxidative Stress and Regulating the AMPK/Nrf2 Pathway Regulation

Schisandrin A ameliorates MPTP-induced Parkinson’s disease in a mouse model via regulation of brain autophagy

Highly Oxidized and Rearranged Schinortriterpenoids with Neuroprotective Activity from the Stems and Leaves of Schisandra Chinensis

The Protective Mechanism of Schisandrin A in D-Galactosamine-Induced Acute Liver Injury Through Activation of Autophagy

The extraction, purification, structural features, bioactivities, and applications of Schisandra chinensis polysaccharides: A review

Computational pharmacology and bioinformatics to explore the potential mechanism of Schisandra against atherosclerosis

Extraction, purification, structural characterization, and biological activity of polysaccharides from Schisandra chinensis: A review

Anti‐proliferative Properties of Schinensilactone A, A Schnortriterpenoid with 7, 8‐Seco ‐1,8‐cyclo Scaffold against Caco‐2 by Inducing Cell Apoptosis from the Leaves of Schisandra chinensis

Exploring the Molecular Mechanism of Schisandrin C for the Treatment of Atherosclerosis via the PI3K/AKT/mTOR Autophagy Pathway

Lignans of Schisandra chinensis (Turcz.) Baill inhibits Parkinson's disease progression through mediated neuroinflammation-TRPV1 expression in microglia

Schisandrin A Alleviates Spatial Learning and Memory Impairment in Diabetic Rats by Inhibiting Inflammatory Response and Through Modulation of the PI3K/AKT Pathway

Extraction, purification, structural characterization, and bioactivities of the genus Schisandra polysaccharides: A review

Schisantherin A Exhibits Anti-inflammatory Properties by Down-Regulating NF - κB and MAPK Signaling Pathways in Lipopolysaccharide-Treated RAW 264.7 Cells

A systematic review on triterpenoids from genus Schisandra : Botany, traditional use, pharmacology and modern application

Schisandrin A Alleviates Non-Alcoholic Fatty Liver Disease by Improving Liver Metabolic Disorders and Suppressing the GSK3β Signaling Pathway

A comprehensive review of ethnopharmacology, phytochemistry, pharmacology, and pharmacokinetics of Schisandra chinensis (Turcz.) Baill. and Schisandra sphenanthera Rehd. et Wils.